Clinical Trial Update: Optimal Duration of Clopidogrel in Second-Generation Drug-Eluting Stents [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluated the optimal duration of clopidogrel after implantation of second-generation drug-eluting stents. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ischemic Heart Disease

Drugs mentioned

• CLOPIDOGREL (CLOPIDOGREL)
• Plavix (clopidogrel)

Snippet

Sponsor: Gangnam Severance Hospital | Conditions: Ischemic Heart Disease | Phase 4 | Status: COMPLETED